meropenem fresenius kabi 500 mg inj./inf. sol. (pwdr.) i.v. vial
fresenius kabi sa-nv - meropenem trihydrate 570 mg - eq. meropenem 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570 mg - meropenem
meronem iv 500 mg inj./inf. sol. (pwdr.) i.v. vial
pfizer sa-nv - meropenem trihydrate 570 mg - eq. meropenem 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570 mg - meropenem
meropenem bradex 500 mg inj./inf. sol. (pwdr.) i.v.
bradex s.a. - meropenem trihydrate 570 mg - eq. meropenem anhydrous 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570 mg - meropenem
meropenem ranbaxy 500 mg inj./inf. sol. (pwdr.) i.v. vial
ranbaxy (uk) (5) ltd. - meropenem trihydrate 570 mg - eq. meropenem anhydrous 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570 mg - meropenem
meropenem- meropenem injection, powder, for solution
hospira, inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - meropenem for injection i.v. is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection i.v. is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , bacteroides fragilis , b. thetaiotaomicron , and peptostreptococcus species. meropenem for injection i.v. is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae , neisseria meningitidis, and penicillin-susceptible isolates of streptococcus pneumoniae. meropenem for injection i.v. has been found to be effective in eliminating co
meropenem- meropenem injection, powder, for solution
daewoong america inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 20 ml - meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of stre
meropenem- meropenem injection, powder, for solution
fresenius kabi usa, llc - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - meropenem for injection, usp (i.v.) is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , bacteroides fragilis , b. thetaiotaomicron , and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae , neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae . meropenem for injection, usp (i.v.) has been found to be
meropenem apotex meropenem (as trihydrate) 500 mg powder for injection vial
arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 570.5 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia
meropenem apotex meropenem (as trihydrate) 1000 mg powder for injection vial
arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 1141 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia
meropenem ranbaxy meropenem (as trihydrate) 500mg powder for injection vial
sun pharma anz pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections, - complicated skin and skin structure infections, - meningitis, - septicaemia.